29 May 2024
29 May 2024
J&J has made its second dermatology deal this month, adding Numab’s bispecific antibody NM26 to its growing atopic dermatitis drug portfolio.
The speed and flexibility required in clinical trials for COVID-19 set a new precedent for what can be achieved in fighting infectious diseases. From collaborative digital platforms to utilizing AI, GlobalData examines some of the key trends affecting contract research organizations (CROs).
The monoclonal antibody works by binding to the complement C5 protein, preventing the breakdown of red blood cells.
Cartography is entitled to receive $20m upfront, followed by additional near-term preclinical milestone payments.
HanAll's initial investment in Turn Bio in 2022 laid the groundwork for this expanded collaboration.
Nearly 37% of subjects experienced serious treatment-emergent adverse events, with thrombocytopenia and interstitial lung disease (ILD) being notable events.
M-Trace Software can alert pharmaceutical manufacturers to any errors detected during the testing process.
Currently in a Phase IIa study, AV-001 is being co-developed with AnGes for the prevention and treatment of ARDS in pneumonia.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
